Efficacy comparison between primary and secondary ITP
| Variable . | Primary ITP (n = 122) . | Secondary ITP (n = 16) . | Statistical significance (P value) . |
|---|---|---|---|
| Quality of response | |||
| Patients with a platelet response, n (%) | 98 (80.3%) | 11 (68.7%) | .537 |
| Response stratified by variables | |||
| Fostamatinib monotherapy vs use in combination | |||
| Fostamatinib monotherapy | 63 (87.5%) | 6 (66.7%) | .234 |
| Fostamatinib use in combination | 34 (69.4%) | 5 (71.4%) | .913 |
| Platelet count at fostamatinib initiation (<20 × 109/L vs ≥20 × 109/L) | |||
| <20 × 109/L | 40 (69%) | 3 (50%) | .385 |
| ≥20 × 109/L | 55 (90.2%) | 8 (80%) | .313 |
| Patients with a complete platelet response, n (%) | 67 (55.4%) | 7 (43.8%) | .381 |
| Number of days to platelet response, median (IQR) | 11 (7-21) | 21 (9-22) | .044 |
| Number of days to platelet response stratified by variables | |||
| Prior therapy with rituximab | |||
| Yes | 21 (14-36) | 22 (21-54) | .126 |
| No | 9 (7-15) | 14 (8-20) | .874 |
| Fostamatinib monotherapy vs use in combination | |||
| Monotherapy | 11 (7-19) | 21 (11-22) | .438 |
| Combination | 14 (8-28) | 17 (10-22) | .109 |
| Variable . | Primary ITP (n = 122) . | Secondary ITP (n = 16) . | Statistical significance (P value) . |
|---|---|---|---|
| Quality of response | |||
| Patients with a platelet response, n (%) | 98 (80.3%) | 11 (68.7%) | .537 |
| Response stratified by variables | |||
| Fostamatinib monotherapy vs use in combination | |||
| Fostamatinib monotherapy | 63 (87.5%) | 6 (66.7%) | .234 |
| Fostamatinib use in combination | 34 (69.4%) | 5 (71.4%) | .913 |
| Platelet count at fostamatinib initiation (<20 × 109/L vs ≥20 × 109/L) | |||
| <20 × 109/L | 40 (69%) | 3 (50%) | .385 |
| ≥20 × 109/L | 55 (90.2%) | 8 (80%) | .313 |
| Patients with a complete platelet response, n (%) | 67 (55.4%) | 7 (43.8%) | .381 |
| Number of days to platelet response, median (IQR) | 11 (7-21) | 21 (9-22) | .044 |
| Number of days to platelet response stratified by variables | |||
| Prior therapy with rituximab | |||
| Yes | 21 (14-36) | 22 (21-54) | .126 |
| No | 9 (7-15) | 14 (8-20) | .874 |
| Fostamatinib monotherapy vs use in combination | |||
| Monotherapy | 11 (7-19) | 21 (11-22) | .438 |
| Combination | 14 (8-28) | 17 (10-22) | .109 |
Platelet response and complete platelet response variables with statistically significant differences are indicated in bold.